• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

131 例滤泡淋巴瘤患者接受匹配无关供者干细胞移植:来自欧洲血液和骨髓移植学会淋巴瘤工作组的分析。

Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

机构信息

Department of Hematology and Bone Marrow Transplantation, Rambam Medical Centre and Technion, Haifa, Israel.

出版信息

Br J Haematol. 2009 Dec;147(5):719-28. doi: 10.1111/j.1365-2141.2009.07905.x. Epub 2009 Sep 30.

DOI:10.1111/j.1365-2141.2009.07905.x
PMID:19793383
Abstract

Matched unrelated donor stem cell transplantation (MUD-SCT) provides the only curative option for patients with follicular lymphoma (FL) who fail conventional therapies and do not have a sibling donor. The purpose of this study was to analyse the outcome of patients with FL treated with MUD-SCT included in the European Group for Blood and Marrow Transplantation registry. 131 patients treated with reduced-intensity conditioning (RIC, n = 87) or conventional myeloablative (CONV, n = 44) MUD-SCT between 2000 and 2005 were included. Median time from diagnosis to MUD-SCT was 47 months and the median number of previous therapeutic regimens was 4 (previous autograft: 47%). RIC recipients were significantly older, with a longer interval from diagnosis to MUD-SCT and had failed a previous autograft more frequently than CONV recipients. Non-relapse mortality (NRM) was 24% and 30% at 100-d and 1-year, respectively. After a median follow-up of 36 months, 17% of the patients developed disease progression, the 3-year progression-free survival (PFS) being 47%. Three-year overall survival (OS) for the whole series was 51%. On multivariate analysis, RIC regimens were associated with at lower NRM and a significantly longer PFS and OS. This retrospective study demonstrated that MUD-SCT results, even in heavily pre-treated populations, in a meaningful PFS and OS.

摘要

无关供者造血干细胞移植(MUD-SCT)为常规治疗失败且无同胞供者的滤泡性淋巴瘤(FL)患者提供了唯一的治愈选择。本研究旨在分析欧洲血液和骨髓移植学会登记处纳入的接受 MUD-SCT 治疗的 FL 患者的结局。2000 年至 2005 年间,纳入了 131 例接受低强度预处理(RIC,n=87)或常规清髓性预处理(CONV,n=44)MUD-SCT 的患者。从诊断到 MUD-SCT 的中位时间为 47 个月,中位治疗方案数为 4 个(既往自体移植:47%)。RIC 组患者年龄明显更大,从诊断到 MUD-SCT 的时间间隔更长,且既往自体移植失败的频率高于 CONV 组。非复发死亡率(NRM)在 100 天和 1 年时分别为 24%和 30%。中位随访 36 个月后,17%的患者发生疾病进展,3 年无进展生存率(PFS)为 47%。全组 3 年总生存率(OS)为 51%。多因素分析显示,RIC 方案与较低的 NRM 以及更长的 PFS 和 OS 相关。这项回顾性研究表明,即使在预处理较重的人群中,MUD-SCT 也能带来有意义的 PFS 和 OS。

相似文献

1
Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.131 例滤泡淋巴瘤患者接受匹配无关供者干细胞移植:来自欧洲血液和骨髓移植学会淋巴瘤工作组的分析。
Br J Haematol. 2009 Dec;147(5):719-28. doi: 10.1111/j.1365-2141.2009.07905.x. Epub 2009 Sep 30.
2
Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.异基因造血细胞移植治疗蕈样肉芽肿和赛泽里综合征患者:欧洲血液和骨髓移植学会淋巴瘤工作组的回顾性分析。
J Clin Oncol. 2010 Oct 10;28(29):4492-9. doi: 10.1200/JCO.2010.29.3241. Epub 2010 Aug 9.
3
Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.在复发或难治性弥漫性大 B 细胞淋巴瘤患者中进行减低强度异基因造血干细胞移植后的低非复发死亡率和长期生存延长:法国骨髓和细胞治疗移植协会的报告。
Biol Blood Marrow Transplant. 2010 Jan;16(1):78-85. doi: 10.1016/j.bbmt.2009.09.002. Epub 2009 Sep 8.
4
Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.与传统异基因干细胞移植相比,减低强度预处理用于复发或难治性霍奇金淋巴瘤的疗效分析:欧洲血液与骨髓移植组淋巴瘤工作组的一项研究
J Clin Oncol. 2008 Jan 20;26(3):455-62. doi: 10.1200/JCO.2007.13.2415. Epub 2007 Dec 17.
5
Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphoma.全清髓性异基因干细胞移植治疗滤泡性淋巴瘤的总生存率良好。
Biol Blood Marrow Transplant. 2008 Jul;14(7):775-82. doi: 10.1016/j.bbmt.2008.04.007.
6
Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor.来自人类白细胞抗原(HLA)匹配的无关供体的减低强度造血干细胞移植的可行性
Bone Marrow Transplant. 2004 Apr;33(7):697-702. doi: 10.1038/sj.bmt.1704425.
7
Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response.复发或高级别滤泡性淋巴瘤患者进行自体移植可实现长期无病生存,并获得最佳的中位缓解持续时间。
Ann Hematol. 2005 Aug;84(8):526-31. doi: 10.1007/s00277-005-1058-9. Epub 2005 May 25.
8
Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up.异基因造血干细胞移植联合低强度预处理方案治疗难治性和复发性多发性骨髓瘤患者:长期随访结果。
Cancer. 2010 Aug 1;116(15):3621-30. doi: 10.1002/cncr.25228.
9
Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant.在先前自体移植失败的成年患者中,采用减低剂量预处理进行第二次异基因外周血干细胞移植后,移植相关死亡率较低。
Bone Marrow Transplant. 2002 Jul;30(2):63-8. doi: 10.1038/sj.bmt.1703606.
10
Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.异基因干细胞移植治疗成人骨髓增生异常综合征:移植前疾病负担的重要性。
Biol Blood Marrow Transplant. 2009 Jan;15(1):30-8. doi: 10.1016/j.bbmt.2008.10.012.

引用本文的文献

1
Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma.异基因造血干细胞移植联合氟达拉滨和马法兰治疗高危 B 细胞非霍奇金淋巴瘤的 II 期临床试验结果。
Clin Lymphoma Myeloma Leuk. 2023 Sep;23(9):e268-e276. doi: 10.1016/j.clml.2023.05.011. Epub 2023 May 23.
2
A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?精准表观遗传疗法治疗滤泡性和弥漫性大B细胞淋巴瘤的前景可期?
Blood Lymphat Cancer. 2022 Aug 4;12:99-106. doi: 10.2147/BLCTT.S282247. eCollection 2022.
3
CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products.
用于B细胞淋巴瘤的嵌合抗原受体T细胞疗法:现有产品的临床试验结果
Ther Adv Hematol. 2019 Apr 15;10:2040620719841581. doi: 10.1177/2040620719841581. eCollection 2019.
4
Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies.帕萨昔布,一种强效且高度选择性的 PI3Kδ 抑制剂,用于治疗复发或难治性 B 细胞恶性肿瘤患者。
Blood. 2019 Apr 18;133(16):1742-1752. doi: 10.1182/blood-2018-08-867499. Epub 2019 Feb 25.
5
Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas?异基因造血细胞移植治疗淋巴瘤是否需要进行骨髓清除剂量强度?
Bone Marrow Transplant. 2017 Nov;52(11):1487-1494. doi: 10.1038/bmt.2017.55. Epub 2017 Apr 3.
6
Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.氟达拉滨、环磷酰胺和大剂量利妥昔单抗用于滤泡性淋巴瘤异基因造血细胞移植的减低强度预处理:血液与骨髓移植临床试验网络的一项二期多中心试验
Biol Blood Marrow Transplant. 2016 Aug;22(8):1440-1448. doi: 10.1016/j.bbmt.2016.04.014. Epub 2016 Apr 23.
7
Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas.异基因造血细胞移植作为非转化性滤泡淋巴瘤的治愈性疗法。
Bone Marrow Transplant. 2016 May;51(5):654-62. doi: 10.1038/bmt.2015.348. Epub 2016 Feb 8.
8
The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months.对于缓解期持续时间≤12个月的极早期复发难治性滤泡性淋巴瘤患者,异基因移植相对于自体移植的潜在益处。
Br J Haematol. 2016 Apr;173(2):260-4. doi: 10.1111/bjh.13947. Epub 2016 Feb 5.
9
A prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignancies.一项针对含阿仑单抗的减低强度异基因干细胞移植方案用于高危及晚期淋巴系统恶性肿瘤患者的前瞻性研究。
Leuk Lymphoma. 2014 Dec;55(12):2739-47. doi: 10.3109/10428194.2014.894185. Epub 2014 Mar 20.
10
Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma.在复发弥漫性大 B 细胞淋巴瘤中,匹配的无关供体异基因移植与 HLA 完全匹配的同胞供体移植提供可比的长期结果。
Bone Marrow Transplant. 2014 May;49(5):671-8. doi: 10.1038/bmt.2014.4. Epub 2014 Feb 10.